Point of care with serial NT-proBNP measurement in patients with acute decompensated heart failure as a therapy-monitoring during hospitalization (POC–HF): Study protocol of a prospective, unblinded, randomized, controlled pilot trial

• DOI: 10.1016/j.conctc.2021.100825
• Publication Date: 2021-08-19T18:19:27Z
• Authors: Stephanie Züsli; Frederick Bierreth; Maria Boesing; Philippe Haas; Kristin Abig; Sabrina Maier; Giorgia Corridori; Jörg D. Leuppi; Thomas Dieterle
• Keywords: Vital signs; Clinical endpoint

Despite important advances in diagnosis and medical therapy of heart failure (HF), disease monitoring guidance remains to be based on clinical signs symptoms. NT-proBNP was repeatedly demonstrated a strong independent predictor morbidity mortality patients with HF. Only few – conflicting data are available the efficacy serial measurement as tool for treatment These limited outpatient setting. Currently, no effects this approach hospitalized acute decompensated The goal study is explore whether availability measurements may influence decisions HF, leads more rapid dose adjustments prognostically beneficial therapies earlier hospital discharge. In intervention group, every second business day performed made treating physician, while control group. HF left at discretion physician. primary endpoints defined decisions, including type dosing rapidity adjustments, length stay, evaluation changes values. Additional secondary include incidence electrolyte imbalances renal failure, NYHA functional class, vital signs, body weight, quality life, adverse events, transfer Intensive Care Units, mortality.